Atlas Blog
Insights on FDA inspections, compliance strategy, and regulatory intelligence from the Atlas team.
Atlas
About 25% of pharma and medical device organizations are piloting AI for regulatory and compliance review — but the model isn't the constraint. Legacy QMS data, process variation, and budget framing are where adoption stalls.
Atlas
Your QMS vendor just shipped an AI module, and the demo focused on the model. But infrastructure, change management, and QMS-ERP integration — the technologistics layer above the model — are where most AI rollouts in regulated quality functions succeed or fail.
Atlas
The CEO came back from a conference and wants an AI strategy for quality. The honest, board-ready version is 5 lines: one capability shipped, one pilot named, one thing you're explicitly not doing, your data integrity approach, and what you'll know by the next board meeting.
Atlas
Most FDA inspection risks come from missed guidance updates, fragmented monitoring, and lack of evidence that regulatory changes were tracked. A dedicated guidance monitoring database like Hedwig centralizes global guidance, tracks updates and withdrawals, and creates inspection-ready evidence of continuous monitoring.
Atlas
Every compliance team wants to be proactive. They want to spot changes early, assess impact quickly, and act before an investigator raises an issue.
Atlas
The shift from paper to electronic logs (eLogs) and electronic batch records (eBMRs) is accelerating across pharma manufacturing.
Atlas
AI can help generate procedures and Root Cause Analysis (RCA) reports, but AI-generated documents are not automatically FDA-compliant. Compliance depends on system design, data provenance, human oversight, and validation.
Atlas
Yes, LLM-based quality systems can pass an FDA Part 11 audit, but only with validation of intended use, controlled inputs and outputs, ALCOA+ data integrity, audit trails, rigorous change control, and human oversight. This guide walks through the controls and artifacts you need.
Atlas
AI-driven inspection models will enable FDA audits to be faster, more data-driven, and more focused on high-risk signals.
Atlas
Repeat FDA violations keep showing up across drug, biologic, and device manufacturers because problems are systemic, including weak quality systems, sloppy data integrity, poor documentation, and inadequate CAPA and training.
Atlas
Between 2024 and 2025, the FDA shifted from pandemic-era stop-start inspection tactics to a sustained, more aggressive, data-driven, and technology-enabled oversight posture for foreign facilities.
Atlas
Across 2024 and 2025 FDA inspections, the biggest documentation failures involve data integrity and poor recordkeeping: missing batch records, altered lab data, weak CAPA investigations, and incomplete deviation files. This post covers what investigators are finding and how to fix it.
Atlas
The FDA's new internal generative-AI assistant ELSA (Enterprise Language Support Assistant) is an agency-wide tool launched in June 2025 to help reviewers, investigators, and scientists read, summarize, and prioritize large volumes of regulatory and safety data faster.
Atlas
Weak CAPA and investigation systems drive a high share of Form 483s and warning letters. This guide breaks down why investigations stop at "human error," how regulators read CAPA records, and the specific procedure, RCA, and governance fixes that make the system audit-ready.
Atlas
In May 2025 the FDA expanded unannounced inspections at foreign manufacturing sites. This piece breaks down the six reasons behind the shift, what the agency actually said, the investigator workforce reality, and how pharma and medical device manufacturers should respond.
